Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: Relationship to risedronate treatment

Bone

Volumn 36, Issue 3, 2005, Pages 549-554

  Mossetti, Giuseppe ^a   Rendina, Domenico ^a   De Filippo, Gianpaolo ^b   Viceconti, Roberto ^a   Di Domenico, Gilda ^a   Cioffi, Michele ^c   Postiglione, Loredana ^a   Nunziata, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AORN Rummo   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Interleukin 6 system; Osteoprotegerin system; Paget's disease of bone; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE; CLODRONIC ACID; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RISEDRONIC ACID;

ACUTE DISEASE; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MALE; PAGET BONE DISEASE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REMISSION; TREATMENT OUTCOME;

EID: 15544379426     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.11.004     Document Type: Article

References (37)

1. S.V. Reddy, N. Kurihara, C. Menaa, and G.D. Roodman Paget's disease of bone: a disease of the osteoclast Rev. Endocr. Metab. Disord. 2 2001 195 201
2. S.V. Reddy, C. Menaa, F.R. Singer, A. Demulder, and G.D. Roodman Cell biology of Paget's disease J. Bone Miner. Res. 14 2 1999 3 8
3. J.A. Hoyland, A.J. Freemont, and P.T. Sharpe Interleukine-6, Interleukine-6 receptor and IL-6 nuclear factor gene expression in Paget disease J. Bone Miner. Res. 9 1994 75 80
4. C. Menaa, S.V. Reddy, N. Kurihara, H. Maeda, D. Anderson, and T. Cundy Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone J. Clin. Invest. 105 2000 1833 1838
5. S.A. Jones, S. Horiuchi, N. Topley, N. Yamamoto, and G.M. Fuller The soluble interleukin 6 receptor: mechanism of production and implication in disease FASEB J. 15 2001 43 58
6. K.J. Kallen The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases Biochim. Biophys. Acta 1592 2002 323 334
7. T. Jostock, J. Mullberg, S. Ozbek, R. Atreya, G. Blinn, and N. Voltz Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses Eur. J. Biochem. 268 2001 160 167
8. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
9. L.C. Hofbauer, and A.E. Heufelder The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases J. Clin. Endocrinol. Metab. 85 2000 2355 2363
10. S. Khosla The OPG/RANKL/RANK system Endocrinology 142 2001 5050 5055
11. S. Kwan Tat, M. Padrines, S. Theoleyre, D. Heymann, and Y. Fortun IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology Cytokine Growth Factor Rev. 15 2004 49 60
12. G.D. Roodman, N. Kurihara, Y. Ohsaki, A. Kukita, D. Hosking, and A. Demulder Interleukin 6 a potential autocrine/paracrine factor in Paget's disease of bone J. Clin. Invest. 89 1992 46 52
13. R.G.G. Russell, M.J. Rogers, J.C. Frith, S.P. Luckman, F.P. Coxon, and H.L. Benford The pharmacology of bisphosphonates and new insights into their mechanism of action J. Bone Miner. Res. 14 1999 53 65
14. M. Zaidi, H.C. Blair, B.S. Moonga, E. Abe, and C.L. Huang Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics J. Bone Miner. Res. 18 2003 599 609
15. A.J. Yates, R.C. Percival, R.E. Gray, R.M. Atkins, G.H. Urwin, and N.A. Hamdy Intravenous clodronate in the treatment and retreatment of Paget's disease of bone Lancet 1 1985 1474 1477
16. F.R. Singer, T.L. Clemens, R.A. Eusebio, and P.J. Bekker Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease J. Clin. Endocrinol. Metab. 83 1998 1906 1910
17. D. Rendina, G. Mossetti, R. Viceconti, M. Sorrentino, and V. Nunziata Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates Calcif. Tissue Int. 75 2004 189 196
18. M. Davie, M. Davies, R. Francis, W. Fraser, D. Hosking, and R. Tansley Paget's disease of bone: a review of 889 patients Bone 24 1999 11S 12S
19. D.J. Prockop, and S. Underfried A specific method for the analysis of hydroxyproline in tissue and urine Anal. Biochem. 1 1960 228
20. J. Clery, and R.A. Sanders A simplified procedure for the measurement of total hydroxyproline in urine Clin. Chim. Acta 57 1974 217
21. S.A. Khan, E.V. McCloskey, K.S. Eyres, K. Nakatsuka, P. Sirtori, and J. Orgee Comparison of three regimens of clodronate in Paget disease of bone J. Bone Miner. Res. 11 1996 178 182
22. D.H. Gutteridge, L.C. Ward, G.O. Stewart, R.W. Retallack, R.K. Will, and R.L. Prince Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another J. Bone Miner. Res. 2 1999 79 84
23. S.A. Glantz Primer of biostatistics 2001 McGraw-Hill/Appleton and Lange New York
24. D. Rendina, L. Postiglione, P. Vuotto, F.G. Numis, G. Di Domenico, and R. Viceconti Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone Clin. Exp. Rheumatol. 20 2002 359 364
25. L. Alvarez, P. Peris, N. Guanabens, S. Vidal, I. Ros, and F. Pons Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates Arthritis Rheum. 48 2003 824 828
26. D. Santini, M.E. Fratto, B. Vincenzi, A. La Cesa, C. Dianzani, and G. Tonini Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities BioDrugs 18 2004 269 278
27. G. Dicuonzo, B. Vincenzi, D. Santini, G. Avvisati, L. Rocci, and F. Battistoni Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 J. Interferon Cytokine Res. 23 2003 649 654
28. R.G. Russell, and M.J. Rogers Bisphosphonates: from the laboratory to the clinic and back again Bone 25 1999 97 106
29. C.J. Dunn, and K.L. Goa Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease Drugs 61 2001 685 712
30. C. Crandall Risedronate: a clinical review Arch. Intern. Med. 161 2001 353 360
31. H. Fleisch Development of bisphosphonates Breast Cancer Res. 4 2002 30 34
32. D. Santini, Vespasiani, U. Gentilucci, B. Vincenzi, A. Picardi, and F. Vasaturo The antineoplastic role of bisphosphonates: from basic research to clinical evidence Ann. Oncol. 14 2003 1468 1476
33. V. Viereck, G. Emons, V. Lauck, K.H. Frosch, S. Blaschke, and C. Grundker Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts Biochem. Biophys. Res. Commun. 291 2002 680 686
34. N. Makkonen, A. Salminen, M.J. Rogers, J.C. Frith, A. Urtti, and E. Azhayeva Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite Eur. J. Pharm. Sci. 8 1999 109 118
35. R.D. Altman Paget's disease of bone F.L. Coe M.J. Favus Disorders of bone and mineral metabolism second ed. 2002 Lippincot Williams and Wilkins Philadelphia, PA 985 1020
36. E.S. Siris Goals of treatment for Paget's disease of bone J. Bone Miner. Res. 14 1999 49 52
37. P.L. Selby, M.W.J. Davie, S.H. Ralston, and M.D. Stone Guidelines on the management of Paget's disease of bone Bone 31 2002 366 373